본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

Biomolecules & therapeutics v.18 no.3, 2010년, pp.343 - 349   SCIE SCOPUS 피인용횟수: 1
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Pharmacokinetic Drug Interaction between Carvedilol and Ticlopidine in Rats

Choi, Jun-Shik    (College of Pharmacy, Chosun University   ); Choi, Dong-Hyun    (College of Medicine, Chosun University  );
  • 초록

    This study was designed to investigate the effects of ticlopidine on the pharmacokinetics of carvedilol after oral or intravenous administration of carvedilol in rats. Carvedilol was administered orally (3 mg/kg) or intravenously (1 mg/kg) without or with oral administration of ticlopidine (4, 12 mg/kg) to rats. The effects of ticlopidine on P-glycoprotein (P-gp) and cytochrome P450 (CYP) 2C9 activity were also evaluated. Ticlopidine inhibited CYP2C9 activity in a concentration-dependent manner with 50% inhibition concentration ( $IC_{50}$ ) of $25.2\;{\mu}M$ . In addition, ticlopidine could not significantly enhance the cellular accumulation of rhodamine 123 in MCF-7/ADR cells overexpressing P-gp. Compared with the control group (given carvedilol alone), the area under the plasma concentration-time curve (AUC) was significantly (12 mg/kg, p $C_{max}$ ) was significantly (12 mg/kg, p


  • 주제어

    Carvedilol .   Ticlopidine .   CYP2C9 .   P-glycoprotein .   Pharmacokinetics .   Bioavailability.  

  • 참고문헌 (34)

    1. Bart, J., Dijkers, E. C., Wegman, T. D., de Vries, E. G., van der Graaf, W. T., Groen, H. J., Vaalburg, W., Willemsen, A. T. and Hendrikse, N. H. (2005). New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics. Br. J. Pharmacol. 145, 1045-1051. 
    2. Bristow, M. R., Gilbert, E. M., Abraham, W. T., Adams, K. F., Fowler, M. B., Hershberger, R. E., Kubo, S. H., Narahara, K. A., Ingersoll, H., Krueger, S., Young, S. and Shusterman, N. (1996). Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 94, 2807-2816. 
    3. Bristow, M. R., Larrabee, P., Minobe, W., Roden, R., Skerl, L., Klein, J., Handwerger, D. and Port, J. D., Muller-Beckmann B. (1992). Receptor pharmacology of carvedilol in the human heart. J. Cardiovasc. Pharmacol. 19, S68-80. 
    4. Buur, T., Larsson, R., Berglund, U., Donat, F. D. V. M. and Tronquet, C. (1997). Pharmocokinetics and effect of ticlopidine on platelet aggregation in subjects with normal and impaired renal function. J. Clin. Pharmacol. 37, 108-115. 
    5. Cao, X,, Gibbs, S. T., Fang, L., Miller, H. A., Landowski, C. P, Shin, H. C., Lennernas, H., Zhong, Y., Amidon, G. L., Yu, L. X. and Sun, D. (2006). Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. 23, 1675-1686. 
    6. Cleland, J. G., Bristow, M. R., Erdmann, E., Remme, W. J., Swedberg, K. and Waagstein, F. (1996). Beta-blocking agents in heart failure. Should they be used and how? Eur. Heart J. 17, 1629-1639. 
    7. Cournot, A., Lim, C., Duchier, J. and Safar, M. (1992). Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects. J. Cardiovasc. Pharmacol. 19, S35-39. 
    8. Crespi, C. L., Miller, V. P., Penman, B. W. (1997). Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 248, 188-190. 
    9. DasGupta, P., Broadhurst, P. and Lahiri, A. (1991). The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure. J. Cardiovasc. Pharmacol. 18, S12-16. 
    10. Feuerstein, G. Z., Bril, A. and Ruffolo, R. R. Jr. (1997). Protective effects of carvedilol in the myocardium. Am. J. Cardiol. 80, 41L-45L. 
    11. Gent, M., Blakely, J. A., Easton, J. D., Ellis, D. J., Hachinski, V. C., Harbison, J. W., Panak, E., Roberts, R. S., Sicurella, J. and Turpie, A. G. (1989). The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet. 1, 1215-1220. 
    12. Gidal, B. E., Sorkness, C. A., McGill, K. A., Larson, R. and Levine, R. R. (1995). Evaluation of a potential enantioselective interaction between ticlopidine and warfarin in chronically anticoagulated patients. Ther. Drug Monit. 17, 33-38. 
    13. Hampton, J. R. (1996). Beta-blockers in heart failure--the evidence from clinical trials. Eur. Heart J. 17, 17-20. 
    14. Hass, W. K., Easton, J. D., Adams, H. P. Jr., Pryse-Phillips, W., Molony, B. A., Anderson, S. and Kamm, B. (1989). A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N. Engl. J. Med. 321, 501-507. 
    15. Haynes, R. B., Sandler, R. S., Larson, E. B., Pater, J. L. and Yatsu, F. M. (1998). A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Arch. Intern. Med. 152, 1376-1380. 
    16. Ito, M. K., Smith, A. R. and Lee, M. L. (1992). Ticlopidine: a new platelet aggregation inhibitors. Clin. Pharm. 11, 603-617. 
    17. Janzon, L., Bergqvist, D., Boberg, J., Boberg, M., Eriksson, I., Lindgarde, F., Persson, G., Almgren, B., Fagher, B. and Kjellstrom, T., et al. (1990). Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J. Intern. Med. 227, 301-308. 
    18. Kaminsky, L. S. and Fasco M. J. (1991). Small intestinal cytochromes P450. Crit. Rev. Toxicol. 21, 407-422. 
    19. Ko, J. W., Desta, Z., Soukhova, N. V., Tracy, T. and Flockhart, D. A. (2000). In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C9 and CYP2D6. Br. J. Clin. Pharmacol. 49, 343-351. 
    20. Kolars, J. C., Schmiedlin-Ren, P., Schuetz, J. D., Fang, C. and Watkins, P. B. (1992). Identification of rifampin-inducible P450IIIA4 (CYP2C9) in human small bowel enterocytes. J. Clin. Invest. 90, 1871-1878. 
    21. Lewis, D. F. V. (1996). Cytochrome P450. Substrate specificity and metabolism. In Cytochromes P450. Structure, Function, and Mechanism, pp. 122-123. Taylor & Francis, Bristol. 
    22. Lund-Johansen, P., Omvik, P., Nordrehaug, J. E. and White, W. (1992). Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure. J. Cardiovasc. Pharmacol. 19, S27-34. 
    23. McGinnity, D., Tucker, J., Trigg, S. and Riley, R. (2005). Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. Drug Metab. Dispos. 33, 1700-1707. 
    24. McTavish, D., Campoli-Richards, D. and Sorkin, E. M. (1993). Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 45, 232-258. 
    25. Morgan, T. (1994). Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin. Pharmacokinet. 26, 335-346. 
    26. Neugebauer, G., Akpan, W., von Mollendorff, E., Neubert, P. and Reiff, K. (1987). Pharmacokinetics and disposition of carvedilol in humans. J. Cardiovasc. Pharmacol. 11, S85-88. 
    27. Neugebauer, G. and Neubert, P. (1991). Metabolism of carvedilol in man. Eur. J. Drug Metab. Pharmacokinet. 16, 257-260. 
    28. Oldham, H. G. and Clarke, S. E. (1997). In vitro identification of the human cytochrome P450 enzymes involved in the meta-bolism of R(+)- and S(-)-carvedilol. Drug Metab. Dispos. 25, 970-977. 
    29. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R. and Komano, T. (1993). P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS. Lett. 324, 99-102. 
    30. Saltiel, E. and Ward, A. (1987). Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutics efficacy in platelet-dependent disease states. Drugs 34, 222-262. 
    31. Shah, J., Fratis, A., Ellis, D., Murakami, S. and Teitelbaum, P. (1990). Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride. J. Clin. Pharmacol. 30, 733-736. 
    32. Solomon, D. H. and Hart, R. G. (1994). Antithrombotic therapies for stroke prevention. Curr. Opin. Neurol. 7, 48-53. 
    33. Verhaeghe, R. (1991). Prophylactic antiplatelet therapy in peripheral arterial disease. Drugs 42, 51-57. 
    34. Zarghi, A., Foroutan, S. M., Shafaati, A. and Khoddam, A. (2007). Quantification of carvedilol in human plasma by liquid chromatography using fluorescence detection: application in pharmacokinetic studies. J. Pharm. Biomed. Anal. 44, 250-253. 
  • 이 논문을 인용한 문헌 (1)

    1. 2011. "" Biomolecules & therapeutics, 19(2): 237~242     

 저자의 다른 논문

  • Choi, Jun-Shik (129)

    1. 1973 "국소마취제(局所麻醉劑)가 Sulfanilamide의 직장내(直腸內) 흡수(吸收)에 미치는 영향" 대한약리학잡지 9 (1): 53~58    
    2. 1974 "Chymotrypsin 및 Trypsin 농도(濃度)에 따른 Sulfadimethoxine의 흡수(吸收)와 배설(排泄)에 관(關)한 연구(硏究)" 藥劑學會誌 = Journal of Korean pharmaceutical sciences 4 (1): 31~38    
    3. 1975 "Proteolytic Enzyme이 Pyrazinamide의 흡수(吸收), 배설(排泄)에 미치는 영향(影響)" 藥劑學會誌 = Journal of Korean pharmaceutical sciences 5 (4): 24~31    
    4. 1976 "Ethanol의 농도(濃度)에 따른 Sulfadimethoxine의 흡수(吸收)와 배설(排泄)에 관한 연구(硏究)" 藥劑學會誌 = Journal of Korean pharmaceutical sciences 6 (1): 18~25    
    5. 1977 "Alloxan Diabetes 동물(動物)에서의 Sulfisoxazole의 흡수(吸收)와 배설(排泄)에 관(關)한 연구(硏究)" 藥劑學會誌 = Journal of Korean pharmaceutical sciences 7 (1): 22~27    
    6. 1979 "병태동물(病態動物)에서 Oxytetracycline의 생물약제학적(生物藥劑學的) 연구(硏究)" 藥劑學會誌 = Journal of Korean pharmaceutical sciences 9 (2): 1~10    
    7. 1980 "발열성(發熱性) 물질(物質)이 Antipyrin과 Ampicillin의 생체이용률(生體利用率)에 미치는 영향(影響)" 藥劑學會誌 = Journal of Korean pharmaceutical sciences 10 (3): 27~32    
    8. 1981 "피임제(避妊劑) 제형(製型) 개발(開發)에 관(關)한 연구(硏究)(I)" 藥劑學會誌 = Journal of Korean pharmaceutical sciences 11 (3): 14~20    
    9. 1982 "유화제(乳化劑)와 Lidocaine.HCl의 병용효과에 관(關)한 연구(硏究)( I )" 藥劑學會誌 = Journal of Korean pharmaceutical sciences 12 (2): 31~36    
    10. 1982 "Liposome-Insulin의 토끼직장투여(直腸投與)에 있어서 혈당치(血糖値)의 변화(變化)" 藥劑學會誌 = Journal of Korean pharmaceutical sciences 12 (3): 88~92    
  • Choi, Dong-Hyun (10)

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • NDSL :
  • 한국응용약물학회 : 저널
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기